SACRAMENTO: Gilead Sciences Inc. and Immunomedics have entered into a definitive agreement pursuant to which Gilead will acquire Immunomedics for $88/share in cash. The transaction, which values Immunomedics at approximately $21 billion, was unanimously approved by both the Gilead and Immunomedics Boards of Directors and is anticipated to close during the fourth quarter of 2020….
Search Results for: FDA Approval
Liberty Health to launch edible cannabis products
TORONTO: Liberty Health Sciences Inc., a provider of high-quality cannabis, announced that pending approval from the Florida Department of Agriculture (FDACS) and Department of Health, the Company will be expanding its product line with the introduction of edible cannabis products. Liberty plans to introduce an assortment of edibles including cookies, chocolates, pretzels, chips, bars, lozenges,…
Dr. Reddy’s Laboratories enters into a licensing agreement with Gilead Sciences for Remdesivir
PRINCETON: Dr. Reddy’s Laboratories has entered into a non-exclusive Licensing Agreement with Gilead Sciences, Inc. (Gilead) that will grant Dr. Reddy’s the right to register, manufacture and sell Gilead’s investigational drug, Remdesivir, a potential treatment for Covid-19, in 127 countries including India. Dr. Reddy’s will receive technology transfer from Gilead for manufacturing of this drug….
Victory Square Technologies portfolio company acquired the assets and intellectual properties of Safetest Comércio de Diagnósticos
VANCOUVER: Victory Square Health Inc. – a wholly-owned subsidiary and portfolio company of Victory Square Technologies Inc. — has acquired the assets and intellectual properties of Safetest Comércio de Diagnósticos Ltd in an all-stock transaction. Per the terms of the agreement, VS Health has agreed to acquire Safetest assets and intellectual properties for $4,000,000 CAD…
Biolidics appoints Mediproud for distribution of Novel Coronavirus 2019 antibody test kits in Thailand
SINGAPORE: Biolidics Limited has entered into a distribution agreement with Mediproud Co., Ltd, a company incorporated in Thailand, to appoint Mediproud as a non-exclusive distributor for the Company’s test kits for the detection of the Novel Coronavirus 2019 antibodies (the “COVID-19 Antibody Test Kits”), in Thailand for a duration of one year. The Company’s COVID-19…
Moderna and Lonza announce strategic collaboration to manufacture vaccine against Novel Coronavirus
BASEL, SWITZERLAND: Moderna Inc., a clinical stage biotechnology company, and Lonza Ltd. have announced a 10-year strategic collaboration agreement to enable larger scale manufacture of Moderna’s mRNA vaccine (mRNA-1273) against the novel coronavirus (SARS-CoV-2) and additional Moderna products in the future. Under the terms of the agreement, the companies plan to establish manufacturing suites at…
Hikma and Glenmark sign agreement to commercialise Ryaltris
LONDON: Hikma Pharmaceuticals and Glenmark Specialty, a Swiss subsidiary of Glenmark Pharmaceuticals, announced the signing of an exclusive US license agreement to commercialise Ryaltris (olopatadine hydrochloride and mometasone furoate nasal spray), an investigational fixed-dose combination nasal spray for the treatment of seasonal allergic rhinitis (SAR). Under the terms of the agreement, Glenmark will be responsible…
Beximco Pharma launches fifth product in the US market
LONDON: Beximco Pharmaceuticals Limited, the fast-growing manufacturer of generic pharmaceutical products and active pharmaceutical ingredients, has commenced export of a blood pressure drug, Nadolol, to the US market. Nadolol tablets (20mg, 40mg and 80mg) are the generic equivalent of Bristol-Myers Squibb’s Corgard tablets for treating hypertension and angina pectoris (chest pain). This is Beximco’s fifth…